HHS Selects 15 New Drugs for Medicare Part D Price Negotiations
· 4d · on MSN
Latest Medicare price drug negotiations includes Ozempic, Wegovy
Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started, so current drug prices are unaffected.
Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo Nordisk blockbusters Wegovy and Ozempic, are slated for price talks.
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.
Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.
The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.
Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team, has died at 65. | Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current transition team,
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce prescription drug costs.
A new Health and Human Services report is calling for greater transparency in long-term care ownership, calling out private equity investors.
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations.
Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and stronger."
The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback